Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 11,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $52.01, for a total value of $572,110.00. Following the sale, the chairman now directly owns 48,014 shares in the company, valued at approximately $2,497,208.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of Ionis Pharmaceuticals Inc (NASDAQ IONS) traded up $0.56 on Wednesday, hitting $51.61. 621,132 shares of the stock were exchanged, compared to its average volume of 1,034,773. The firm has a market capitalization of $6,420.00, a price-to-earnings ratio of 368.64 and a beta of 2.86. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21. Ionis Pharmaceuticals Inc has a 1-year low of $37.26 and a 1-year high of $65.51.
Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Ionis Pharmaceuticals by 4.4% in the second quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after purchasing an additional 417,364 shares in the last quarter. BlackRock Inc. raised its position in Ionis Pharmaceuticals by 4.0% in the second quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after purchasing an additional 264,179 shares in the last quarter. American Century Companies Inc. raised its position in Ionis Pharmaceuticals by 33.0% in the third quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after purchasing an additional 284,266 shares in the last quarter. First Trust Advisors LP raised its position in Ionis Pharmaceuticals by 40.2% in the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after purchasing an additional 281,733 shares in the last quarter. Finally, Northern Trust Corp raised its position in Ionis Pharmaceuticals by 7.8% in the second quarter. Northern Trust Corp now owns 621,816 shares of the company’s stock worth $31,631,000 after purchasing an additional 44,750 shares in the last quarter. 91.40% of the stock is owned by institutional investors and hedge funds.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.